Cardiovascular risk of cyclooxygenase-2 inhibitors and traditional nonsteroidal anti-inflammatory drugs

被引：24

作者：

Hermann, Matthias ^{[1
]}

Ruschitzka, Frank ^{[1
]}

机构：

[1] Univ Zurich Hosp, Cardiovas Ctr, CH-8091 Zurich, Switzerland

来源：

ANNALS OF MEDICINE | 2007年 / 39卷 / 01期

关键词：

cardiovascular risk; coxibs; hypertension; NSAIDs;

D O I：

10.1080/07853890601073445

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Since selective cyclooxygenase-2 inhibitors (coxibs) entered the market, there has been concern about the cardiovascular safety of coxibs. In addition, recent data suggest that classical non-steroidal anti-inflammatory drugs (NSAIDs) have a similar cardiovascular risk. Importantly, all of the clinical trials with NSAIDs and coxibs so far were not purpose-designed to specifically and prospectively address cardiovascular safety and were clearly underpowered to detect any meaningful differences. In this current uncertainty about safety of NSAIDs and coxibs, the definitive answer as to the net effect of coxibs and NSAIDs on cardiovascular events can only be provided by well designed adequately powered, long-term clinical trials, which is now under way.

引用

页码：18 / 27

页数：10

共 48 条

[31] Cyclooxygenase-2 inhibition and cardiovascular events
Pitt, B
Pepine, C
Willerson, JT
[J]. CIRCULATION, 2002, 106 (02) : 167 - 169
[32] COX-2 selective non-steroidal anti-inflammatory drugs and risk of serious coronary heart disease
Ray, WA
Stein, CM
Daugherty, JR
Hall, K
Arbogast, PG
Griffin, MR
[J]. LANCET, 2002, 360 (9339) : 1071 - 1073
[33] Comparison of cardiovascular thrombotic events in patients with osteoarthritis treated with rofecoxib versus nonselective nonsteroidal anti-inflammatory drugs (ibuprofen, diclofenac, and nabumetane)
Reicin, AS
Shapiro, D
Sperling, RS
Barr, E
Yu, QF
[J]. AMERICAN JOURNAL OF CARDIOLOGY, 2002, 89 (02) : 204 - 209
[34] Comparison of lumiracoxib with naproxen and ibuprofen in the Therapeutic Arthritis Research and Gastrointestinal Event Trial (TARGET), reduction in ulcer complications: randomised controlled trial
Schnitzer, TJ
Burmester, GR
Mysler, E
Hochberg, MC
Doherty, M
Ehrsam, E
Gitton, X
Krammer, G
Mellein, B
Matchaba, P
Gimona, A
Hawkey, CJ
[J]. LANCET, 2004, 364 (9435) : 665 - 674
[35] Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis - The CLASS study: A randomized controlled trial
Silverstein, FE
Faich, G
Goldstein, JL
Simon, LS
Pincus, T
Whelton, A
Makuch, R
Eisen, G
Agarwal, NM
Stenson, WF
Burr, AM
Zhao, WW
Kent, JD
Lefkowith, JB
Verburg, KM
Geis, GS
[J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2000, 284 (10): : 1247 - 1255
[36] Singh G, 2005, ANN RHEUM DIS, V64, P85
[37] Relationship between COX-2 specific inhibitors and hypertension
Solomon, DH
Schneeweiss, S
Levin, R
Avorn, J
[J]. HYPERTENSION, 2004, 44 (02) : 140 - 145
[38] Relationship between selective cyclooxygenase-2 inhibitors and acute myocardial infarction in older adults
Solomon, DH
Schneeweiss, S
Glynn, RJ
Kiyota, Y
Levin, R
Mogun, H
Avorn, J
[J]. CIRCULATION, 2004, 109 (17) : 2068 - 2073
[39] Cardiovascular risk associated with celecoxib in a clinical trial for colorectal adenoma prevention
Solomon, SD
McMurray, JJV
Pfeffer, MA
Wittes, J
Fowler, R
Finn, P
Anderson, WF
Zauber, A
Hawk, E
Bertagnolli, M
[J]. NEW ENGLAND JOURNAL OF MEDICINE, 2005, 352 (11) : 1071 - 1080
[40] The effects of cyclooxygenase-2 inhibitors and nonsteroidal anti-inflammatory therapy on 24-hour blood pressure in patients with hypertension, osteoarthritis, and type 2 diabetes mellitus
Sowers, JR
White, WB
Pitt, B
Whelton, A
Sinion, LS
Winer, N
Kivitz, A
van Ingen, H
Brabant, T
Fort, JG
[J]. ARCHIVES OF INTERNAL MEDICINE, 2005, 165 (02) : 161 - 168

← 1 2 3 4 5 →